A randomized double-blind placebo-controlled trial of the efficiency and mechanism of bumetanide on children with Autism Spectrum Disorder

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16009627

Enrollment

Unknown

Registered

2016-10-26

Start date

2016-10-27

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Interventions

Group A:bumetanide

Group B:Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients, aged from 2.5 to 6 years old, were given the diagnosis of ASD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) , by a team of autism experts; Scores for Children Autism Rating Scale (CARS) were more than 30; Signed Informed Consents were provided by parents.

Exclusion criteria

Exclusion criteria: Liver and kidney dysfunction; With a history of allergy to sulfa drugs; abnormal ECG; chromosomal abnormality; suffering from nervous system diseases (such as epilepsy, schizophrenia, and so on); using the melatonin treatment for sleep disorders or withdrawal less than three weeks

Design outcomes

Primary

Measure	Time frame
CARS score;	—

Secondary

Measure	Time frame
SSP score;CDI score;SPT score;CGI score;SRS score;ADOS score;	—

Countries

China

Contacts

Public ContactFei Li

Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

feili@shsmu.edu.cn+86 18930830950

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026